QIAGEN N.V.’s (QGEN) first-quarter 2024 adjusted earnings per share (EPS) were 46 cents and 47 cents at constant exchange rate (CER), down 9.8% year over year. However, the figure topped the Zacks Consensus Estimate by 4.6%.The adjustment excludes the impact of certain non-recurring items like business integration, acquisition and restructuring-related expenses, purchased intangible amortization expenses and non-cash interest expense charges, among others.The GAAP EPS for the quarter was 36 cents, down 2.7% ...

For the quarter ended March 2024, Qiagen (QGEN) reported revenue of $458.8 million, down 5.5% over the same period last year. EPS came in at $0.46, compared to $0.53 in the year-ago quarter.The reported revenue represents a surprise of +0.73% over the Zacks Consensus Estimate of $455.5 million. With the consensus EPS estimate being $0.44, the EPS surprise was +4.55%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

Qiagen (QGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.55%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.56 per share when it actually produced earnings of $0.55, delivering a surprise of -1.79%.Over the last four quarters, the ...

Wall Street analysts forecast that Qiagen (QGEN) will report quarterly earnings of $0.44 per share in its upcoming release, pointing to a year-over-year decline of 17%. It is anticipated that revenues will amount to $454.97 million, exhibiting a decline of 6.3% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this time ...

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connection - Click here: C ...

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connection - Click here: ...

QIAGEN N.V. (QGEN) recently announced a sequence of new products to augment cancer research further and to enable urine collection and stabilization as a new approach for liquid biopsy. The three new products, coupled with the IVD version of QIAGEN's digital PCR platform QIAcuity, are planned to be released in mid-2024.The new products are likely to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San Diego, California, from Apr 5-10.Product DetailsThe first produc ...

Venlo, the Netherlands, April 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a series of new products to further enhance cancer research as well as to enable urine collection and stabilization as a new approach for liquid biopsy. These three new products, along with the IVD version of QIAGEN's digital PCR platform QIAcuity set for launch in mid-2024, are to be featured at the annual meeting of the American Association for Cancer Research (AACR) in San D ...

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements. A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers. This collaboration f ...

Market Performance - QIAGEN's year-end market capitalization was $9,911 million, equivalent to €8,991 million[20]. - The share price declined by 13% to $43.43 on the NYSE and by 16% to €39.40 on the Frankfurt Stock Exchange[22]. - The average daily trading volume was approximately 1.5 million shares, with 1.0 million in the U.S. and 0.5 million in Germany[23]. - The free float of QIAGEN shares was approximately 99% as of December 31, 2023[23]. - QIAGEN's shares have been traded on the NYSE since 2018 and on the Frankfurt Stock Exchange since 1997[19]. Financial Performance - Total net sales for QIAGEN in 2023 were $1,965.3 million, down from $2,141.5 million in 2022, reflecting a decrease of approximately 8.2%[60]. - Molecular Diagnostics sales were $1,035.5 million in 2023, a decline of 8.1% from $1,126.2 million in 2022[60]. - Life Sciences sales decreased to $929.8 million in 2023 from $1,015.3 million in 2022, representing a decline of 8.4%[60]. - Total net sales for 2023 were $1.965 billion, reflecting an 8% decline compared to $2.142 billion in 2022, primarily due to a 66% drop in COVID-19 product sales[108][112]. - Gross profit for 2023 was $1.234 billion, an 11% decrease from $1.385 billion in 2022, with a gross margin of 62.8% compared to 64.7% in the previous year[122][123]. - The operating income margin decreased to 20.9% in 2023 from 24.8% in 2022, attributed to lower sales contributions and higher operating expenses[112][127]. Sales Breakdown - Consumables and related revenues accounted for 88% of total net sales in 2023, while instruments and related services made up 12%[51]. - Consumables and related revenues accounted for $1,726.2 million in 2023, down from $1,888.9 million in 2022, representing a decline of 8.6%[77]. - Instrumentation sales were $239.1 million in 2023, a decrease of 5.3% from $252.6 million in 2022[77]. - The United States generated $935.3 million in net sales in 2023, an increase of 2.5% from $909.6 million in 2022[78]. - Sales in the Diagnostic Solutions product group grew 6% to $697.6 million, driven by strong performance of the QuantiFERON-TB test, which grew 24%[115]. Market Opportunities - The addressable global market for QIAGEN's portfolio is estimated to exceed $11 billion[40]. - The molecular diagnostics market is expected to provide significant growth opportunities, driven by the increasing demand for accurate testing solutions[63]. - The addressable Life Sciences and Molecular Diagnostics industry segments generate an estimated $11 billion in annual sales, with expected single-digit sales growth in the coming years[48]. Research and Development - Research and development investments totaled $11.1 million in 2023, with a focus on expanding Sample to Insight solutions in Molecular Diagnostics[84][97]. - Research and development expenses increased by 5% to $198.5 million, representing 10.1% of net sales, up from 8.9% in 2022[127]. - The company is developing a deep pipeline of assays for preventive screening and diagnostic profiling, targeting unmet needs in healthcare and research labs[85]. - The QIAcuity digital PCR system is being developed to make digital PCR technology accessible to Life Sciences laboratories worldwide[85]. Strategic Partnerships and Acquisitions - QIAGEN has over 30 master collaboration agreements with pharmaceutical companies for co-development of companion diagnostics, indicating strong partnerships in the industry[64]. - The company expanded its portfolio of assays following FDA approval of a companion diagnostic for Blueprint Medicines, enhancing its market offerings[65]. - The company has made several acquisitions, with purchase prices allocated based on estimated fair values at acquisition dates[173]. - The company made significant investments in production capacity expansion and R&D, including acquisitions of Verogen, Inc. and BLIRT S.A.[109][110]. Operational Challenges - Global economic conditions, including inflation and rising interest rates, pose risks to the company's operations and financial condition[206]. - The ongoing geopolitical conflicts and trade restrictions could disrupt the supply chain and increase costs, impacting overall business performance[206]. - Future operating results will depend on the successful integration of acquired businesses and the ability to address new operational challenges[204]. - The company is assessing the need for resource reallocation and hiring to manage growth and operational expansion effectively[201]. Cash Flow and Financial Position - Net cash provided by operating activities was $459.5 million in 2023, down from $715.3 million in 2022[141]. - Cash and cash equivalents decreased to $668.1 million in 2023 from $730.7 million in 2022[140]. - Total cash and cash equivalents and short-term investments decreased to $1,057.8 million in 2023 from $1,418.3 million in 2022[140]. - Long-term debt as of December 31, 2023, was $1.5 billion, with $0.6 billion classified as current[149]. - Total lease obligations amount to $109.9 million, with $25.1 million classified as current as of December 31, 2023[154]. Shareholder Returns - A synthetic share repurchase returned $295.2 million to shareholders, reducing the total number of issued Common Shares by approximately 3% to 223.9 million as of January 31, 2024[157]. - The company expects cash from financing activities to be influenced by common share issuances related to equity compensation plans and potential future acquisitions[159]. - The company has not paid any dividends since inception and does not plan to do so in the foreseeable future[162].